Tower Research Capital LLC (Trc) Unicycive Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 22,782 shares of UNCY stock, worth $15,491. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,782
Previous 18,485
23.25%
Holding current value
$15,491
Previous $9,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding UNCY
# of Institutions
31Shares Held
46.8MCall Options Held
0Put Options Held
0-
Octagon Capital Advisors LP New York, NY8.56MShares$5.82 Million0.85% of portfolio
-
Great Point Partners LLC Greenwich, CT8.56MShares$5.82 Million1.62% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$3.45 Million0.28% of portfolio
-
Walleye Capital LLC Plymouth, MN5MShares$3.4 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.47MShares$3.04 Million0.27% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $10.2M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...